Frequency of skin diseases in renal transplant recipients and patients with chronic kidney disease in a tertiary center: a cross-sectional study

ABSTRACT BACKGROUND: The prevalence of chronic kidney disease (CKD) has increased in the recent decades, along with the number of patients in the terminal stages of this disease, requiring transplantation. Some skin disorders are more frequent in patients with CKD and in renal transplant recipients (RTR). OBJECTIVES: To evaluate the frequency of skin diseases in RTR and patients with CKD receiving conservative treatment. DESIGN AND SETTING: This observational cross-sectional study recruited consecutive patients with CKD and RTR from a nephrology clinic at a teaching hospital in Brazil between 2015 and 2020. METHODS: Quantitative, descriptive, and analytical approaches were used. The sample was selected based on convenience sampling. Data were collected from dermatological visits and participants' medical records. RESULTS: Overall, 308 participants were included: 206 RTR (66.9%, median age: 48 years, interquartile range [IQR] 38.0-56.0, 63.6% men) and 102 patients with CKD (33.1%, median age: 61.0 years, IQR 50.0-71.2, 48% men). The frequency of infectious skin diseases (39.3% vs. 21.6% P = 0.002) were higher in RTR than in patients with CKD. Neoplastic skin lesions were present in nine (4.4%) RTR and in only one (1.0%) patient with CKD. Among the RTR, the ratio of basal cell carcinoma to squamous cell carcinoma was 2:1. CONCLUSIONS: This study revealed that an increased frequency of infectious skin diseases may be expected in patients who have undergone kidney transplantation. Among skin cancers, BCC is more frequently observed in RTR, especially in those using azathioprine.

Respuesta terapéutica del HeberFERON® en pacientes con carcinoma basocelular y su asociación con la COVID-19

Introducción: El carcinoma basocelular constituye uno de los tipos de cáncer cutáneo de mayor incidencia. El uso del HeberFERON® ha demostrado una efectiva respuesta clínica. Objetivo: Evaluar la respuesta del HeberFERON® en pacientes con carcinoma basocelular asociado a la COVID-19, y su comportamiento en pacientes con igual diagnóstico dermatológico sin tratamiento previo con dicho fármaco, atendidos con cirugía. Materiales y métodos: Se realizó un estudio observacional descriptivo y retrospectivo en un universo de 184 pacientes adultos con carcinoma basocelular. Se analizaron las variables edad, sexo, fototipo de piel, comorbilidades asociadas, infección con SARS-CoV-2 asociada con tratamiento previo con HeberFERON® o cirugía; tiempo entre tratamiento recibido y padecimiento de COVID-19, y severidad de los síntomas. Los resultados se expresan en tablas. Resultados: Se estudiaron 94 pacientes tratados con HeberFERON® para el carcinoma basocelular, y 90 pacientes tratados con cirugía. Predominaron los masculinos, mayores de 60 años, fototipo de piel II-III, con comorbilidades cardiovasculares. De ellos, 24 (25,5 %) resultaron positivos a la COVID-19, y el 83,3 % desarrollaron síntomas leves. De los tratados con cirugía para el carcinoma basocelular, 61 resultaron positivos a la COVID-19 (67,7 %), y el 55,7 % tuvo sintomatología severa. Durante el ciclo de tratamiento con HeberFERON para el carcinoma basocelular, el 66,7 % enfermó con COVID-19 entre las 16 y 32 semanas. Posterior a las 32 semanas, se reportó un fallecido. Conclusiones: Los pacientes tratados con cirugía sin previo HeberFERON tuvieron más contagios con COVID-19, predominando los decesos asociados a ello, siendo menor en los que lo recibieron. De los tratados previamente con HeberFERON® para el carcinoma basocelular, el 74,5 % no enfermó de COVID-19, a pesar de haber sido el 52,8 % contactos de positivos al SARS-CoV-2.

Introduction: Basal cell carcinoma is one of the types of skin cancer with the highest incidence. The use of HeberFERON® has shown an effective clinical response. Objective: To evaluate the response of HeberFERON® in patients with BCC associated with COVID-19 and its behavior in patients with the same dermatological diagnosis without previous treatment with that drug, treated with surgery. Materials and methods: A descriptive and retrospective observational study was conducted in a universe of 184 adult patients with basal cell carcinoma. The variables analyzed were age, sex, skin phototype, associated comorbidities, SARS-CoV-2 infection, associated to previously treatment with HeberFERON® or surgery; time between treatment received and suffering from COVID-19; severity of symptoms. The results were expressed in tables. Results: 94 patients were treated with HeberFERON® for basal cell carcinoma, and 90 were treated with surgery. There was a predominance of male patients, aged over 60 years, skin phototype II-III, with cardiovascular morbidities. Of them, 24 (25.5%) were positive to COVID-19 (67.7%), and 83.3% developed mild symptoms. Of those treated with surgery for basal cell carcinoma, 61 were positive to COVID-19 (67,7%), and 55.7% had severe symptoms. During the HeberFERON® treatment cycle for basal cell carcinoma, 66.7% became ill with COVID-19 between 16 and 32 weeks. After 32 weeks one deceased was reported. Conclusions: Patients treated with surgery without prior HeberFERON® had more infections with Covid-19, the deaths associated with it predominating, being less in those who received it. Of those previously treated with HeberFERON® for basal cell carcinoma, 74.5% did not become ill with COVID-19, despite having been 52.8% contacts to SARS-CoV-2 positive people.

Carcinoma basocelular de la piel cabelluda tratado con HeberFERON. Seguimiento clínico, ecográfico e histopatológico

Fundamento: El carcinoma basocelular es infrecuente en la piel cabelluda. Es un tumor de invasión local y crecimiento lento, puede ser agresivo, destruir tejidos vecinos, causar ulceración e invadir en profundidad cartílago y hueso. Objetivo: Evaluar los resultados de la aplicación del HeberFERON y el seguimiento con ecografía cutánea en pacientes con carcinoma basocelular en la piel cabelluda. Metodología: Se realizó un estudio observacional, descriptivo y longitudinal en una serie de casos con diagnóstico de carcinoma basocelular de la piel cabelluda en el Policlínico Centro de la ciudad Sancti Spíritus, durante el período de 10 de julio del 2018 a 29 de julio del 2022. Se incluyeron 6 casos. Las variables estudiadas fueron la respuesta al tratamiento mediante la clínica, la ecografía cutánea e histopatología y presencia de eventos adversos. Resultados: Predominó el sexo masculino, subtipo histológico sólido, subtipo clínico nódulo ulcerativo, tamaño del tumor mayor de 30 mm y tiempo de evolución de más de 12 meses; la respuesta al tratamiento en la mayoría de los casos fue parcial. Los eventos adversos fueron dolor y ardor en el sitio de inyección, fiebre, edema y eritema perilesional. Conclusiones: El HeberFERON resultó de utilidad en los pacientes con carcinoma basocelular del cuero cabelludo ya que redujo el tumor en unos casos y en otros lo eliminó. La ecografía permitió la evaluación en tiempo real de la neoplasia; los eventos adversos más frecuentes fueron la fiebre y el dolor en el sitio de inyección, a pesar de ello ningún paciente abandonó el tratamiento.

Background: Basal cell carcinoma is uncommon in the scalp. It is a slow-growing locally invasive tumor, it can be aggressive in destroying neighboring tissues, cause ulceration and invade deep into the cartilage and bone. Objective: To evaluate the results of HeberFERON application and follow-up with cutaneous echographical in patients with scalp basal cell carcinoma. Methodology: An observational, descriptive and longitudinal study was conducted in a series of cases diagnosed with scalp basal cell carcinoma at the Center Polyclinic in Sancti Spíritus city during the period from July 10, 2018 to July 29, 2022. Six clinical cases were included. The studied variables were the answer to the treatment by clinical, cutaneous echographical and histopathology and the presence of adverse events. Results: Male sex predominated, solid histologic subtype, clinical subtype ulcerative nodule, tumor size greater than 30 mm and evolution time of over 12 months; the treatment response in most cases was partial; adverse events were pain and burning at the injection site, fever, edema and perilesional erythema. Conclusion: It was observed that in patients with scalp basal cell carcinoma, the HeberFERON treatment reduced in some cases and eliminated the tumor in others. Echography allowed real-time evaluation of the neoplasm, fever and pain at the injection site were the most frequent adverse events. In spite of this, none of the patients abandoned the therapy.

Resultados del uso de HeberFERON® en pacientes con carcinoma basocelular de alto riesgo en Matanzas

Introducción: El cáncer de piel es la más frecuente de todas las neoplasias. Su incidencia mundial ha aumentado en proporción epidémica, y existe un predominio en países tropicales debido a la constante exposición solar. El carcinoma basocelular es el que más afecta a la población y predomina en hombres de más de 60 años. Existen criterios para clasificar esta entidad en alto riesgo, basándose, sobre todo, en la localización y extensión de la lesión. Una opción novedosa y terapéutica de elección es el uso del HeberFERON®. Objetivo: Describir la respuesta clínica al tratamiento con HeberFERON® en pacientes con carcinoma basocelular de alto riego en Matanzas, en el período de febrero de 2019 a julio de 2021. Materiales y métodos: Se realizó un estudio descriptivo prospectivo en pacientes atendidos en la Consulta Provincial de Tumores Periféricos, de Matanzas, que presentaron carcinoma basocelular de alto riesgo en el período mencionado. Resultado: La población estuvo constituida por 55 pacientes, predominando los hombres y el grupo etario de 60 a 69 años. Las variantes ulceradas localizadas en la nariz constituyeron las formas clínicas agresivas de mayor incidencia. Conclusiones: Imperaron las respuestas completas en tumores mayores de 2 cm, evitando cirugías mutilantes, con lo que se evidencia la seguridad y eficacia del HeberFERON®.

Introduction: Skin cancer is the most frequent of all neoplasms. Its worldwide incidence has increased in epidemic proportions, and there is predominance in tropical countries due to constant sun exposition. Basal cell carcinoma is the one that most affects the population and predominates in men over 60 years of age. There are criteria to classify this entity as high risk, based, above all, in the location and extent of the lesion. A novel and therapeutic option of election is the use of HeberFERON™. Objective: To describe the clinical response to treatment with HeberFERON™ in patients with high-risk basal cell carcinoma in Matanzas, from February 2019 to July 2021. Materials and methods: Prospective, descriptive study was carried out in patients treated at the Provincial Clinic of Peripheral Tumors, of Matanzas, who presented high-risk basal cell carcinoma in the aforementioned period. Results: The population consisted of 55 patients, predominating men and the age group from 60 to 69 years. The ulcerative forms located in the nose constituted the aggressive clinical forms of highest incidence. Conclusions: Complete responses prevailed in tumors larger than 2 cm, avoiding mutilating surgeries, thus demonstrating the safety and efficacy of HeberFERON™.

HeberFERON en el tratamiento de pacientes con carcinoma basocelular en zona de alto riesgo / HeberFERON in the Treatment of Patients with Basal Cell Carcinoma on a High-Risk Zone

Introducción: El carcinoma basocelular es un tumor de invasión local de crecimiento; se origina en las células epidérmicas de los folículos pilosos o las células basales de la epidermis, cuando se localizan en zona de alto riesgo en la cara tienen un mayor índice de recurrencia tumoral y de invasión a estructuras adyacentes y subyacentes. Objetivo: Evaluar los resultados de la aplicación del HeberFERON en pacientes con carcinoma basocelular en zona de alto riesgo. Métodos: Se realizó un estudio observacional, descriptivo y prospectivo en pacientes con diagnóstico clínico, dermatoscópico e histopatológico de carcinoma basocelular en zona de alto riesgo, tratados con HeberFERON en la consulta del Policlínico Centro de Sancti Spíritus desde el 12 de enero de 2016 hasta el 25 de marzo de 2022. La muestra quedó conformada por 62 pacientes Las principales variables estudiadas fueron la respuesta al tratamiento y los eventos adversos. Resultados: Predominó el sexo masculino, el área urbana, fototipocutáneo III y la edad mayor de 40 años. La localización más frecuente fue la nasal; el subtipo clínico el nódulo ulcerativo; el histológico, el sólido; el tumor primitivo y menor de 2 cm; la respuesta al tratamiento fue completa en la mayoría de los pacientes. Los eventos adversos más comunes fueron dolor y ardor en el sitio de inyección, edema y eritema perilesional, fiebre y cefalea. Conclusiones: La mayoría de los pacientes tratados con HeberFERON tuvieron una respuesta completa, los eventos adversos fueron los descritos en la literatura por el uso de interferones, sin cambio en la actitud farmacológica(AU)

Introduction: Basal cell carcinoma is a growing and locally invasive tumor; it originates in the epidermal cells of hair follicles or the basal cells of the epidermis. When located in a high-risk facial zone, they present a higher rate of tumor recurrence and invasion to adjacent and underlying structures. Objective: To evaluate the results of HeberFERON application in patients with basal cell carcinoma on a high-risk zone. Methods: An observational, descriptive and prospective study was conducted in patients with a clinical, dermatoscopic and histopathological diagnosis of basal cell carcinoma on a high-risk zone, treated with HeberFERON in the consultation of Policlínico Centro of Sancti Spíritus, from January 12, 2016 to March 25, 2022. The sample was made up of 62 patients. The main variables studied were response to treatment and adverse events. Results: There was a predominance of the male sex, the urban area, skin phototype III and age over 40 years. The most frequent localization was nasal; the clinical subtype, ulcerative nodule; the histological subtype, solid. The response to treatment was complete in most patients. The most common adverse events were pain and burning at the injection site, perilesional erythema and edema, fever and headache. Conclusions: Most patients treated with HeberFERON had a complete response; the adverse events were those described in the literature due to the use of interferons, with no change in pharmacological behavior(AU)

HeberFERON en el tratamiento de pacientes con carcinoma basocelular de la oreja / HeberFERON in the treatment of patients with basal cell carcinoma of the ear

Fundamento: El carcinoma basocelular de la región auricular es considerado uno de los más agresivos y con peor pronóstico, suele ser destructivo y mutilante por lo que el tratamiento conservador, como es el uso de los interferones, es importante en la práctica médica habitual. Objetivo: Evaluar los resultados de la aplicación del HeberFERON en una serie de pacientes con carcinoma basocelular en la región auricular. Metodología: Se realizó un estudio observacional, descriptivo y longitudinal en una serie de casos con diagnóstico clínico, dermatoscópico e histopatológico de carcinoma basocelular de la oreja que recibieron tratamiento con HeberFERON en el Policlínico Centro de la ciudad Sancti Spíritus, durante el período del 20 de febrero de 2017 a 20 de diciembre de 2022. En total se incluyeron 29 pacientes. Se realizó una evaluación inicial, durante y 16 semanas después del tratamiento; se les inyectó 10.5 UI de HeberFERON 3 veces por semana perilesional e intradérmico hasta completar 9 dosis. Las variables fueron la respuesta al tratamiento y presencia o no de eventos adversos. Resultados: Predominó el sexo masculino, la localización en la concha de la oreja, subtipo clínico nódulo ulcerativo y el histológico sólido, con respuesta completa en la mayoría de los pacientes. Como eventos adversos más comunes se presentaron dolor en el sitio de inyección, fiebre, edema y eritema perilesional. Conclusiones: La respuesta al tratamiento fue favorable en la mayoría de los pacientes y los eventos adversos que se observaron fueron los descritos en la literatura sin cambio en la actitud farmacológica.

Background: Basal cell carcinoma of the auricular region is one of the most aggressive cancers and with the worst prognosis, is usually destructive and mutilating, therefore conservative treatment, such as the use of interferons, is important in routine medical practice. Objective: To evaluate the results of HeberFERON application in a series of patients with basal cell carcinoma in the auricular region. Methodology: An observational, descriptive and longitudinal study was conducted on a series of cases with clinical, dermoscopic and histopathologic diagnosis of basal cell carcinoma of the ear treated with HeberFERON at the Center Polyclinic in Sancti Spíritus city, during the period from February 20, 2017 through December 20, 2022. A total of 29 patients were included in the study. An evaluation was conducted at the start of treatment, during treatment, and 16 weeks after treatment; the patients were treated with 10.5 IU of HeberFERON by perilesional and intradermal injections three times a week until completing nine doses. The variables were the response to the treatment and the presence or absence of any adverse events. Results: The male sex predominated, location in the ear turbinate, clinical subtype ulcerative nodule and solid histologic subtype, with a complete response in the majority of patients. The most common adverse events were injection site pain, fever, edema, and perilesional erythema. Conclusions: The response to treatment was favorable in most patients, and the adverse events observed were those described in the literature, with no change in pharmacologic attitude.

Tratamiento con HeberFERON( en el carcinoma basal palpebral

El carcinoma basal palpebral representa un 90 % de los tumores malignos oculares con una alta morbilidad. Su incidencia tiene un comportamiento diferente en las distintas partes del mundo y, por lo general, aumenta con la edad. El diagnóstico positivo se realiza por la evaluación histológica de la muestra mediante biopsia escisional. El tratamiento ideal es el quirúrgico, aunque existen otras opciones de tratamiento. El no quirúrgico tiene como objetivo la eliminación del tumor, así como evitar las complicaciones o las secuelas funcionales y estéticas por la cirugía. Se reconocen numerosas opciones dentro de la modalidad terapéutica no quirúrgica; imiquimod, 5-fluorouracilo, inhibidores de la vía de Hedgehog y los interferones. Diversos estudios han demostrado la utilidad de los interferones en monoterapia o como terapia combinada, en pacientes no susceptibles de actuaciones quirúrgicas. Por esta razón, se decidió revisar la literatura científica actual sobre la eficacia y seguridad del HeberFERON® en el tratamiento del carcinoma basal palpebral. Se realizó una búsqueda actualizada teniendo en cuenta los descriptores correspondientes a las palabras clave relacionadas con la temática a investigar, en las bases de datos bibliográficas Medline (buscador PubMed), SciELO, Ebsco, Clinical Key y en Google Académico. Se recuperaron 35 artículos que su contenido respondía al tema de estudio.

Palpebral basal carcinoma represents 90% of ocular malignant tumors with high morbidity. Its incidence has a different behavior in different parts of the world and generally increases with age. Positive diagnosis is made by histological evaluation of the specimen by excisional biopsy. The ideal treatment is surgical, although other treatment options are available. Non-surgical treatment is aimed at eliminating the tumor, as well as avoiding the complications or functional and esthetic sequelae of surgery. Numerous options are recognized within the non-surgical therapeutic modality; imiquimod, 5-fluorouracil, Hedgehog pathway inhibitors and interferons. Several studies have demonstrated the usefulness of interferons in monotherapy or as combination therapy in patients not amenable to surgery. For this reason, it was decided to review the current scientific literature on the efficacy and safety of HeberFERON® in the treatment of palpebral basal cell carcinoma. An updated search was carried out taking into account the descriptors corresponding to the key words related to the subject under investigation, in the bibliographic databases Medline (PubMed search engine), SciELO, Ebsco, Clinical Key and Google Scholar. Thirty-five articles were retrieved whose content corresponded to the subject of the study.

Dermoscopic features of basal cell carcinoma in skin of color: A retrospective cross-sectional study from Puducherry, South India

Background: Dermoscopy is useful in the diagnosis of basal cell carcinoma (BCC). However, most descriptions of the dermoscopic features of BCCs are in Caucasians (skin types I-III) and there is a paucity of data in dark-skinned Indian patients. Aims: The aim of this study was to describe the various dermoscopic features of BCC in dark-skinned patients from South India and correlate these with the histopathologic subtypes. Methods: A retrospective observational study of biopsy-proven cases of BCC was conducted at a tertiary care center in South India using nonpolarized contact dermoscopy. Results: Sixty BCCs in 35 patients predominantly of skin phototypes IV or V were studied. These included 32 nodular, 27 superficial and 1 infiltrative type of BCC. The most common dermoscopic features noted were maple leaf-like areas (61.7%), blue-white veils (53.4%), ulceration (48.4%) and short fine telangiectases (46.7%). Ulceration, blue-white veils and arborizing vessels were significantly associated with nodular BCCs, while maple leaf-like areas, red-white structureless areas, multiple small erosions and spoke wheel areas were noted with superficial BCCs. Limitations: The limitations of this study include its retrospective nature, the use of only nonpolarized light for examination, the lack of other histopathological variants of BCC as well as the lack of a comparison group. Conclusion: We report a dermoscopic study of BCC in dark-skinned patients from Puducherry, South India. The blue-white veil was observed in half of the patients and was significantly associated with nodular BCCs. The addition of the blue-white veil to the diagnostic criteria for pigmented BCC could improve the diagnostic accuracy of dermoscopy in Indian patients.

Interpretation of Expert Consensus on Diagnosis and Treatment of Cutaneous Basal Cell Carcinoma (2021) by A Multidisciplinary Team / 肿瘤防治研究

Basal cell carcinoma (BCC) is the most common malignant tumor in dermatology with incidence rising rapidly. Expert consensus on diagnosis and treatment of cutaneous basal cell carcinoma (2021) was published in September 2021 by Skin Tumor Research Center, Chinese Society of Dermatology and Subcommittee on Skin Tumor, China Dermatologist Association. This consensus comprehensively describes the epidemiology, pathogenesis, clinical manifestations, auxiliary examination, pathology, pretreatment assessment, treatment, prognosis, and follow-up education. It offers an important guideline for promoting the standardized diagnosis and treatment of skin BCC in China. In this work, multidisciplinary experts interpreted the main contents of the consensus, including clinicopathological findings, pretreatment assessment, and treatment advance.

Prurito ótico por carcinoma basocelular en conducto auditivo externo / Otic pruritus due to basal cell carcinoma of the external auditory canal

El carcinoma basocelular es el tumor cutáneo más frecuente en el área de cabeza y cuello; la exposición crónica al sol es el factor de riesgo más importante para este tumor. Suele manifestarse clínicamente con síntomas anodinos en estadios iniciales, lo que contribuye a que su diagnóstico sea difícil y tardío. Tiene un comportamiento localmente invasivo, especialmente a nivel del pabellón auricular. Este es el único caso descrito en el conducto auditivo externo no relacionado con la exposición al sol, con características clínicas y terapéuticas que lo hacen peculiar.

Basal cell carcinoma is the most frequent skin tumor in the head and neck area, and chronic sun exposure is the most important risk factor. It usually manifests clinically with anodyne symptoms in the early stages, which contributes to its difficult late diagnosis. It is locally invasive, especially at the level of the pinna. It is the only case described in the external auditory canal not related to sun exposure; it presents clinical and therapeutic characteristics that make it peculiar.

Cirugía micrográfica de Mohs en carcinomas cutáneos: siete años de experiencia en Uruguay / Mohs micrographic surgery in skin cancer: 7 years' experience in uruguay / Cirurgia micrográfica de Mohs em carcinomas cutáneos: 7 anos de experiência no Uruguai

Introducción: la cirugía micrográfica de Mohs es una técnica para la exéresis de cánceres de piel con la ventaja del examen histológico del 100% de los márgenes quirúrgicos, logrando así la tasa de curación más alta con la máxima preservación de tejido sano circundante. Objetivo: realizar una descripción clínico-epidemiológica de 7 años de experiencia en Uruguay. Método: análisis descriptivo de pacientes operados por un mismo cirujano de Mohs registrando datos clínicos, tumorales y quirúrgicos. Resultados: se estudiaron 641 cirugías. 54,9% fueron realizadas en hombres y 45,1% en mujeres. La edad media fue de 69 años. El 68,2% correspondió a carcinoma basocelular y 31,8% a carcinoma espinocelular. El 79,4% se encontraba en cabeza y cuello. El 87,8% de los tumores fueron primarios y un 11,1% recidivas. El tipo más frecuente de cierre fue el cierre simple con 48,7% seguido de los colgajos con un 31,7%. Conclusiones: la cirugía de Mohs es un procedimiento seguro y eficaz, y nuestros resultados coinciden con lo descrito en centros de referencia internacional. Este trabajo describe 7 años de experiencia en Uruguay de la técnica de CMM, siendo el mayor a nivel nacional.

Introduction: Mohs micrographic surgery is a technique for skin cancer exeresis involving the advantage of 100% of surgical margins histological exam, which leads to highest healing rates with the maximum preservation of the surrounding healthy tissue. Objective: to conduct a clinical and epidemiological description of a 7 years' experience in Uruguay. Method: descriptive analysis of patients operated by the same Mohs surgeon who recorded clinical, tumor and surgical data. Results: 641 surgeries were included in the study. 54.9% of surgeries were performed in men and 45.1% in women. Average age was 69 years old. 68.2% of cases corresponded to basal cell carcinoma and 31.8% to squamous cell carcinoma. 79.4% were located in the head and neck, 87.8% of tumors were primary and 11.1% were cases of relapse. The most frequent type of closure was simple in 48.7% of cases, followed by flaps in 31.7%. Conclusions: Mohs surgery is a safe an effective procedure, and the results of the study agree with what is described in international reference centers. The study describes a 7 years' experience in Uruguay of Mohs micrographic surgery, being it the largest research conducted in Uruguay.

Introdução: a cirurgia micrográfica de Mohs é uma técnica de excisão de cânceres de pele com a vantagem do exame histológico de 100% das margens cirúrgicas, alcançando assim a maior taxa de cura com a máxima preservação do tecido saudável circundante. Objetivo: realizar uma descrição clínico-epidemiológica de 7 anos de experiência no Uruguai. Método: análise descritiva de pacientes operados pelo mesmo cirurgião com experiência na técnica de Mohs registrando dados clínicos, tumorais e cirúrgicos. Resultados: foram estudadas 641 cirurgias. 54,9% foram realizados em homens e 45,1% em mulheres. A média de idade foi de 69 anos. 68,2% corresponderam a carcinoma basocelular e 31,8% a carcinoma espinocelular. 79,4% estavam na cabeça e pescoço. 87,8% dos tumores eram primários e 11,1% recidivas. O tipo de fechamento mais frequente foi o fechamento simples (48,7%) seguido do fechamento com retalhos com (31,7%). Conclusões: a cirurgia de Mohs é um procedimento seguro e eficaz, e nossos resultados coincidem com os descritos em centros de referência internacionais. Este trabalho descreve 7 anos de experiência no Uruguai da técnica CMM, sendo a maior a nível nacional.

Efectividad del Heberferon en el tratamiento del carcinoma basocelular

El Carcinoma basocelular es el cáncer de piel más frecuente en el ser humano, representa aproximadamente entre un 70 y un 80 % de los cánceres cutáneos no melanoma en la población de color de piel blanca, este es un tumor maligno de estirpe epitelial y es el más frecuente en la consulta dermatológica, soliendo afectar a individuos mayores de 50 años con máxima incidencia entre la sexta y octava década de la vida. Se realizó un estudio postcomercialización, observacional, de serie de casos, de vigilancia temprana del medicamento en condiciones de práctica médica habitual. La investigación se ejecutó con los pacientes con diagnóstico de carcinoma basocelular, atendidos en la consulta en la consulta de oncodermatología, que tiene su sede Hospital ‟Carlos Manuel de Céspedes" de Bayamo, durante el período comprendido entre enero 2018 a diciembre 2019.El universo estuvo constituido por 120 pacientes y la muestra por 92 pacientes mayores de 18 años, a los que se les administró HeberFERON, resultando ser efectivo en el tratamiento de carcinoma basocelular de cualquier localización, tipo y tamaño. Se confirmó la efectividad en condiciones de práctica médica habitual, en las variables: respuesta clínica al tratamiento, utilizando para ello, los criterios RECIST, además mostró un perfil de seguridad adecuado. Los eventos adversos reportados fueron en su mayoría grado 1 y grado 2, según la clasificación del CTCAE, versión 5 y por su gravedad, se clasificaron no grave.

Basal cell carcinoma is the most frequent skin cancer in humans, representing approximately between 70 and 80% of non-melanoma skin cancers in the white-skinned population, this is a malignant tumor of epithelial lineage and is the most frequent in dermatological consultation, usually affecting individuals over 50 years of age with maximum incidence between the sixth and eighth decade of life. A post-marketing study was conducted, observational, case series, of early surveillance of the drug under conditions of routine medical practice. The research was carried out with patients diagnosed with basal cell carcinoma, attended in the consultation in the oncodermatology consultation, which has its headquarters Hospital ‟Carlos Manuel de Céspedes" of Bayamo, during the period from January 2018 to December 2019. The universe consisted of 120 patients and the sample was 92 patients over 18 years of age, who were administered HeberFERON, proving to be effective in the treatment of basal cell carcinoma of any location, type and size. The effectiveness in conditions of usual medical practice was confirmed, in the variables: clinical response to treatment, using the RECIST criteria, in addition to showing an adequate safety profile. The adverse events reported were mostly grade 1 and grade 2, according to the classification of the CTCAE, version 5 and due to their severity, they were classified as non-serious.

O carcinoma basocelular é o câncer de pele mais frequente em humanos, representando aproximadamente entre 70 e 80% dos cânceres de pele não melanoma na população de pele branca, sendo este um tumor maligno de linhagem epitelial e o mais frequente na consulta dermatológica, acometendo geralmente indivíduos com mais de 50 anos de idade com incidência máxima entre a sexta e a oitava década de vida. Foi realizado um estudo pós-comercialização, observacional, série de casos, de vigilância precoce da droga sobcondições de prática médica de rotina.A pesquisa foi realizada com pacientes diagnosticados com carcinoma basocelular, atendidos na consulta na consulta de oncodermatologia, que temsua sede no Hospital Carlos Manuel de Céspedes, de Bayamo, no período de janeiro de 2018 a dezembro de 2019. O universo foi composto por 120 pacientes e a amostra foi de 92 pacientes com mais de 18 anos de idade, aos quais foi administrado HeberFERON, mostrando-se eficaz no tratamento do carcinoma basocelular de qualquer localização, tipo e tamanho. A efetividade nas condições de prática médica habitual foi confirmada, nas variáveis: resposta clínica ao tratamento, utilizando-se os critérios RECIST, além de apresentarum perfil de segurança adequado. Os eventos adversos relatados foram, em sua maioria, grau 1 e grau 2, de acordo com a classificação do CTCAE, versão 5 e, devido à sua gravidade, foram classificados como não graves.

Efectividad del Heberferon en pacientes con queratosis actínica asociada a carcinoma basocelular

Las queratosis actínicas son neoformaciones dermatológicas planas oexofísticas, presentes mayormente en zonas fotoexpuestas, de evolución crónica y generalmente asintomáticas, siendo la expresión más temprana del carcinoma espinocelular, producidas por la exposición solar crónica en personas fundamentalmente de piel clara. Se realizó un estudio longitudinal prospectivo de intervención terapéutica. El universo estuvo constituido por 130 pacientes y la muestra por 116 pacientes diagnosticados con queratosis actínica que concomitaron con carcinoma basocelular que asistieron a la consulta de oncodermatología del Hospital Provincial Docente "Carlos Manuel de Céspedes" de Bayamo, en el período comprendido de enero 2019 a diciembre 2020; con el objetivo de evaluar la efectividad del tratamiento con HeberFERON® en la queratosis actínica asociada a carcinoma basocelular. Para valorar la asociación entre las variables se empleó el test de Chi Cuadrado de Mantel. Fue frecuente en el estudio el sexo masculino, las edades comprendidas entre 61 y 80 años, el fototipo cutáneo II de la clasificación de Fitzpatrick, que presentaron más de 20 lesiones de queratosis actínica, de localización frecuente en los antebrazos. El HeberFERON fue efectivo y se logró respuesta favorable al tratamiento desde el punto de vista clínico y por dermatoscopia. Los efectos adversos frecuentes tras la administración del HeberFERON® fueron la fiebre, seguido de malestar general y el dolor en el sitio de la inyección.

Actinic keratoses are flat dermatological neoformations or oexofistic, present mostly in photoexposed areas, of chronic evolution and generally asymptomatic, being the earliest expression of squamous cell carcinoma, produced by chronic sun exposure in people mainly fair-skinned. A prospective longitudinal study of therapeutic intervention was conducted. The universe consisted of 130 patients and the sample consisted of 116 patients diagnosed with actinic con queratosis who concomitated with basal cell carcinoma who attended the oncodermatology consultation of the "Carlos Manuel de Céspedes" Provincial Teaching Hospital of Bayamo, in the period from January 2019 to December 2020; with the objective of evaluating the effectiveness of treatment with HeberFERON® in actinic keratosis associated with basal cell carcinoma. To assess the association between the variables, the Mantel Chi-Square test was used. The male sex, ages between 61 and 80 years, cutaneous phototype II of the Fitzpatrick classification, which presented more than 20 lesions of actinic keratosis, of frequent location in the forearms, were frequent in the study. HeberFERON was effective and a favorable response to treatment was achieved from the clinical point of view and by dermoscopy. Common side effects following administration of HeberFERON® were fever, followed by malaise and pain at the injection site.

As ceratoses actínicas são neoformações dermatológicas planas ou oexofísticas, presentes principalmente em áreas fotoexpostas, de evolução crônica e geralmente assintomáticas, sendo a expressão mais precoce do carcinoma espinocelular, produzido pela exposição solar crônica em pessoas principalmente de pele clara. Foi realizado um estudo longitudinal prospectivo de intervenção terapêutica. O universo foi composto por 130 pacientes e a amostra por 116 pacientes diagnosticados com conqueratose actínica que se concomitaram com carcinoma basocelular e que compareceram à consulta de oncodermatologia do Hospital Universitário Provincial "Carlos Manuel de Céspedes" de Bayamo, no período de janeiro de 2019 a dezembro de 2020; com o objetivo de avaliar a eficácia do tratamento com HeberFERON® na queratose actínica associada ao carcinoma basocelular. Para avaliar a associação entre as variáveis, foi utilizado o teste Qui-Quadrado de Mantel. O sexo masculino, com idades entre 61 e 80 anos, o fototipo cutâneo II da classificação de Fitzpatrick, que apresentou mais de 20 lesões de queratose actínica, de localização frequente nos antebraços, foram frequentes no estudo. O HeberFERON foi eficaz e uma resposta favorável ao tratamento foi alcançada do ponto de vista clínico e por dermatoscopia. Os efeitos secundários frequentes após a administração de HeberFERON® foram febre, seguida de mal-estar e dor no local da injeção.

Reconstrucción nasal de lesiones oncológicas. Presentación de dos casos

Se realizó un informe de casos con el objetivo de mostrar la reconstrucción de dos pacientes operados con diagnóstico de carcinoma basocelular en ala nasal, donde se observó la evolución según la modalidad terapéutica empleada tras la resección del tumor. En ambos pacientes se logró la funcionalidad y estética deseadas, con una remoción completa del tumor y garantizando calidad de vida, lo cual es objetivo primordial de la oncología moderna. En pacientes con carcinomas basocelulares la cirugía continúa siendo la mejor opción, con la utilización de colgajos cutáneos para la reparación del defecto, no obstante, debido a sus características, la nariz supone un desafío quirúrgico. No existe un colgajo ideal, se trata de un proceder individualizado, para cada paciente debe planificarse la opción reconstructiva acorde a sus características propias, así como a las del defecto quirúrgico residual.

A case report was made with the aim of showing the reconstruction surgery of two patients with a diagnosis of basal cell carcinoma in nasal ala, in which the evolution was observed according to the therapeutic modality used after tumor resection. In both patients, the functionality and esthetics objectives were achieved, with the completed resection of tumor and with the guarantee of a good quality of life, which is the high priority of modern oncology. In patients with basal cell carcinoma, surgery continues to be the best option with the use of skin flaps to repair the nasal defect; however, due to its characteristics, nasal surgery is a surgical challenge. There is no ideal flap, it is an individualized procedure, and the reconstructive option must be planned according to each patient and their own characteristics, as well as those concerning the residual surgical defect.

Foi feito um relato de caso com o objetivo de mostrar a reconstrução de dois pacientes operados com diagnóstico de carcinoma basocelular em asa nasal, onde foi observada a evolução de acordo com a modalidade terapêutica utilizada após a ressecção do tumor. Em ambos os pacientes, a funcionalidade e estética desejadas foram alcançadas, com remoção completa do tumor e garantia de qualidade de vida, objetivo primordial da oncologia moderna. Nos pacientes com carcinomas basocelulares, a cirurgia continua sendo a melhor opção, com a utilização de retalhos cutâneos para correção do defeito, porém, por suas características, o nariz é um desafio cirúrgico. Não existe retalho ideal, é um procedimento individualizado, para cada paciente a opção reconstrutiva deve ser planejada de acordo com suas características, bem como as do defeito cirúrgico residual.

The use of dermoscopy in distinguishing the histopathological subtypes of basal cell carcinoma: A retrospective, morphological study

Background: The role of dermoscopy in distinguishing the histopathological subtypes of basal cell carcinoma (BCC) is not fully elucidated. Aims: To determine the accuracy of dermoscopy in diagnosing different BCC subtypes. Methods: The dermoscopic features of 102 histopathologically verified BCCs were studied retrospectively. The tumours were classified as superficial (n=33,32.3%), nodular (n=46,45.1%) and aggressive (n=23,22.6%) BCCs by histopathology. Statistical analysis included Cohen’s kappa test, proportion of correlation, measures of diagnostic accuracy, diagnostic odds ratio and the credibility ratio of positive (LR+) and negative (LR?) tests. Results: The highest value in all performed tests was seen in superficial BCCs (kappa 0.85; proportion of correlation 93%; diagnostic accuracy 93.1%), good correlation was noted in nodular BCCs (kappa 0.62, proportion of correlation 80%; diagnostic accuracy 80.4%) but dermoscopic correlation with histopathology was low for aggressive BCCs (kappa 0.13; proportion of correlation 79%; diagnostic accuracy 78.4%). Short, fine telangiectasias (83.3%) showed the greatest importance for the diagnosis of superficial BCCs, blue-grey ovoid nests (61.8%) had the highest diagnostic accuracy in nodular BCCs, while arborising vessels (79.4%) was the most significant dermoscopic feature for the diagnosis of aggressive BCCs. Limitations: This was a retrospective analysis and included only Caucasian patients from a single centre. Conclusion: The highest agreement of dermoscopic features with the histologic type was found in superficial BCCs. We did not find any specific dermoscopic structure that could indicate a diagnosis of aggressive BCC. The presence of relevant dermoscopic features in the evaluated cases was determined by the depth of tumour invasion and not by its histology

Tratamiento del carcinoma basocelular de la nariz con una combinación de interferones Alpha-2b y Gamma / Treatment of basal cell carcinoma of the nose with a combination of Interferon alpha-2b and gamma

Introducción: El carcinoma basocelular es una neoplasia maligna derivada de las células epidérmicas de los folículos pilosos o células no queratinizadas puede ser desfigurante y originar deformidades o pérdida de la función del órgano afectado, es más frecuente en zonas sobresalientes como la nariz. Objetivo: Describir los resultados de la aplicación de la combinación sinérgica de interferones alpha-2b y gamma en una serie de casos con carcinoma basocelular nasal. Material y métodos: Se realizó un estudio de serie de casos clínicos, se incluyeron 28 pacientes con diagnóstico clínico, dermatoscópico e histopatológico de carcinoma basocelular de la nariz que acudieron a consulta de dermatología del Policlínico Centro de Sancti Spíritus en el período de 17 de enero de 2016 a 28 de diciembre de 2021. Se realizó una evaluación inicial y otra final a las 16 semanas después del comienzo del tratamiento. Se administró 10,5 UI de HeberFERON, 3 veces por semana perilesional e intradérmica hasta completar 9 dosis. Las variables principales fueron la respuesta al tratamiento y presencia o no de evento adversos. Resultados: Predominó el sexo masculino, fototipocutáneo II, localización en el dorso y ala nasal, subtipo clínico nódulo ulcerativo y el histológico sólido. En la mayoría de los pacientes desapreció el tumor al culminar el esquema terapéutico. Como eventos adversos más comunes se presentaron dolor en el sitio de inyección, fiebre, edema y eritema perilesional. Conclusiones: La respuesta al tratamiento fue completa en la mayoría de los pacientes y los eventos adversos los descritos en la literatura sin cambios en la actitud farmacológica(AU)

Introduction: Basal cell carcinoma is a malignant neoplasm derived from epidermal cells of hair follicles or non-keratinized cells with a high potential for local destruction, which can be disfiguring and may invade the surrounding tissue, resulting in deformities or loss of function of the affected organ, being more frequent in protruding areas such as the nose. Objective: To describe the results of the application of the synergistic combination of interferon alpha-2b and gamma in a series of cases with nasal basal cell carcinoma. Material and Methods: An observational, descriptive and longitudinal study was carried out in a series of 28 clinical cases with basal cell carcinoma of the nose who attended the dermatology clinic of Policlínico Centro in Sancti Spiritus in the period from january 2016 to december 2021. Cases with a clinical, dermoscopic and histopathological diagnoses were included. An initial and a final evaluation at the end of the 16 weeks of treatment were carried out; also, 10,5 IU of HeberFERON was administered 3 times per week perilesional and intradermally until completing 9 doses. The main variables were response to treatment and presence or absence of adverse events. Results: Male sex, skin phototype II, location on the dorsum and nasal ala, clinical subtype ulcerative nodule, and solid histological subtype predominated. In most of the patients, the tumor disappeared at the end of the therapeutic regime. The most common adverse events were pain at the injection site, fever, edema and perilesional erythema. Conclusions: There was a complete response to treatment in most patients and the adverse events were those described in the literature with no change in the pharmacological attitude(AU)

Caracterización clínico-epidemiológica de pacientes con carcinoma basocelular pertenecientes al área norte de Ciego de Ávila

Introducción: El carcinoma basocelular es el tumor maligno más frecuente, representa aproximadamente entre el 75 y 80 % de todos los cánceres cutáneos no melanoma en la raza blanca. En el área norte de la provincia de Ciego de Ávila no se encuentran estudios sobre este tema. Objetivo: Caracterizar clínica y epidemiológicamente a los pacientes con carcinoma basocelular atendidos en el servicio de Cirugía Maxilofacial del Hospital Provincial Docente "Roberto Rodríguez Fernández" del municipio Morón en la provincia Ciego de Ávila, Cuba, en el período comprendido de enero de 2019 a enero de 2020. Método: Se realizó un estudio observacional descriptivo de corte transversal en 118 pacientes con dicho diagnóstico, donde se estudió: edad, sexo, localización anatómica del tumor, factores predisponentes, formas clínicas de presentación del tumor y estadio clínico. Resultados: Predominó el sexo masculino (60,2 %) y el grupo etario 60-74 años (51,7 %). El 44,1 % del total presentó la forma clínica nodular, con una mayor incidencia en la región nasal 39,8 %. El 97 % de los casos tenía como factor predisponente piel blanca o rosada. La población estudiada se encontró mayormente en estadio clínico II (43,2 %). Conclusiones: Los antecedentes patológicos familiares, exposición solar y piel blanca o rosada influyen marcadamente en la aparición del carcinoma basocelular, lo que permite un adecuado diagnóstico de la enfermedad, así como el desarrollo de actividades de promoción y prevención de salud de estos factores predisponentes.

Introduction: Basal cell carcinoma is the most common malignant tumor, which accounts for approximately 75 or 80 % of all non-melanoma skin cancer in whites. Studies concerning this issue at the northern care area of Ciego de Avila are lacked. Objective: To characterize clinically and epidemiologically all patients with basal cell carcinoma attended in the maxillofacial surgery service at the Hospital Provincial Docente "Roberto Rodríguez Fernández", Morón, Ciego de Ávila, Cuba, from January 2019 to January 2020. Method: A cross-sectional descriptive observational study was conducted in 118 patients with this diagnosis, where the variables studied were as follow: age, sex, the anatomical location of tumor, predisposing factors, clinical forms of tumor and its clinical stage. Results: Male sex (60.2%) and age group 60-74 years (51.7%) were predominant. Nodular clinical form was present in 44.1% of the total, with a higher incidence in the nasal region (39.8%). The predisposing factor in 97% of the cases was white or pink skin. The population studied was mostly in clinical stage II (43.2%). Conclusions: Family pathological history, sun exposure and white or pink skin have a marked influence on the appearance of basal cell carcinoma, which allows an adequate diagnosis of the disease, as well as the development of health promotion and prevention activities for these predisposing factors.

Introdução: O carcinoma basocelular é o tumor maligno mais comum, representando aproximadamente 75-80% de todos os cânceres de pele não melanoma na raça branca. Na zona norte da província de Ciego de Ávila não existem estudos sobre este assunto. Objetivo: Caracterizar clínica e epidemiologicamente os pacientes com carcinoma basocelular atendidos no serviço de Cirurgia Bucomaxilofacial do Hospital Provincial Docente "Roberto Rodríguez Fernández" do município de Morón, província de Ciego de Ávila, Cuba, no período de janeiro de 2019 a janeiro de 2020. Método: Foi realizado um estudo observacional descritivo transversal em 118 pacientes com esse diagnóstico, onde foram estudados idade, sexo, localização anatômica do tumor, fatores predisponentes, formas clínicas de apresentação do tumor e estágio clínico. Resultados: Predominou o sexo masculino (60,2%) e a faixa etária de 60 a 74 anos (51,7%). 44,1% do total apresentaram a forma clínica nodular, com maior incidência na região nasal 39,8%. 97% dos casos tinham a pele branca ou rosada como fator predisponente. A população estudada encontrava-se em sua maioria no estágio clínico II (43,2%). Conclusões: A história patológica familiar, a exposição solar e a pele branca ou rosada têm uma influência marcante no aparecimento do carcinoma basocelular, o que permite um diagnóstico adequado da doença, bem como o desenvolvimento de ações de promoção da saúde e prevenção desses fatores predisponentes.

Cell kinetic markers in cutaneous squamous and basal cell carcinoma of the head and neck / Marcadores cinéticos celulares em carcinomas espinocelulares e basocelulares cutâneos de cabeça e pescoço

Abstract Introduction: Proliferation markers play a significant role in the biologic behavior of tumors. Geminin is a known inhibitor of the cell cycle and DNA replication and has not been previously reported in cutaneous basal and squamous cell carcinomas of the head and neck. Objectives: We aimed to investigate proliferation markers ki67, MCM2, and geminin in head and neck cutaneous basal and squamous cell carcinomas. Methods: Forty cases of each tumor were immuostained with ki67, MCM2, and geminin followed by assessment of labeling indices (LIs). MCM2/ki67- and geminin/ki67-ratios were also determined; t-test was used for statistical analysis (p<0.05). Results: There was no significant difference in ki67 (p = 0.06) and MCM2 (p = 0.46) between cutaneous basal and squamous cell carcinomas; however, geminin LI was significantly higher in squamous cell carcinomas compared to cutaneous basal cell carcinomas (p < 0.001). Only geminin/ki67 showed a significant difference between the two tumors with the ratio showing significantly higher numbers in squamous cell carcinomas (p = 0.015). Conclusions: Geminin could be regarded as an effective factor in the pathogenesis of head and neck cutaneous cutaneous basal cell carcinomas and squamous cell carcinomas and may be one of the responsible elements in the difference between the biologic behavior of these tumors. © 2020 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/).

Resumo Introdução: Marcadores de proliferação têm um papel significativo no comportamento biológico dos tumores. A geminina é um inibidor conhecido do ciclo celular e da replicação do DNA e não foi relatada anteriormente em carcinomas basocelulares e espinocelulares cutâneos de cabeça e pescoço. Objetivo: Investigar os marcadores de proliferação ki67, MCM2 e geminina em carcinomas basocelulares e espinocelulares cutâneos de cabeça e pescoço. Método: Foram submetidos 40a casos de cada tumor à imunocoloração com ki67, MCM2 e geminina, seguida pela avaliação do índice de marcação.Também foram determinadas as razões MCM2/ki67 e geminina/ki67 e o teste t foi usado na análise estatística (p < 0,05). Resultados: Não houve diferença significativa no ki67 (p = 0,06) e no MCM2 (p = 0,46) entre carcinomas basocelulares e espinocelulares; no entanto, o índice de marcação da geminina foi significativamente maior no carcinomas espinocelulares em comparação ao carcinomas basocelulares (p < 0,001). Somente a razão geminina/ki67 mostrou diferença significativa entre os dois tumores, a razão mostrou números significativamente mais altos nos carcinomas espinocelulares (p = 0,015). Conclusões: A geminina pode ser considerada um fator efetivo na patogênese dos carcinomas basocelulares e espinocelulares cutâneos de cabeça e pescoço e pode ser um dos elementos responsáveis pela diferença entre o comportamento biológico desses tumores.

A SURGEON'S SURPRISE TO VERRUCOUS GROWTH OVER CHEEK - CASE REPORT ON MALIGNANT ECCRINE POROMA

Malignant eccrine poroma is a rare malignancy of eccrine glands , whose diagnosis is an index of high suspicion and challenging to a clinician. A case of 67 year old female with swelling over left cheek since 20 years with no radiation exposure and no comorbidities , was investigated and wide local excision with 5mm margins from the tumor was performed , and specimen sent for biopsy - which revealed tumor cells arranged in lobules with peripheral palisading , ductal and squamous differentiation - suggestive of Porocarcinoma.Wide surgical excision is the mainstay of treatment, resulting in cure rates of 70–80% when the margins are clear. Some studies also reported good outcomes with Mohs micrographic surgery, and this technique could also be considered 1. Other treatments such as chemotherapy and radiotherapy have also been reported in the literature without clear standard guidelines

Caracterización de pacientes con cáncer ocular en un hospital de Santiago de Cuba / Characterization of patients with eye cancer in a hospital from Santiago de Cuba i: en

Introducción: La neoplasia ocular puede afectar el ojo, los anexos y la órbita. El tratamiento eficaz depende de un diagnóstico precoz, presuntivo y certero. Objetivo: Caracterizar a los pacientes con cáncer ocular según variables de interés. Método: Se realizó un estudio observacional, descriptivo y retrospectivo de 58 pacientes con tumor maligno ocular, confirmado mediante biopsia, atendidos en el Servicio de Cirugía Plástica Ocular del Centro Oftalmológico del Hospital General Docente Dr. Juan Bruno Zayas Alfonso de Santiago de Cuba, desde octubre del 2015 hasta igual periodo del 2020. Se utilizó la media para las variables cuantitativas. Resultados: En la serie la edad media fue de 62,49 años; primaron el sexo masculino (51,7 %) y el color de la piel mestizo (53,4 %). La localización más frecuente de las lesiones tumorales en los anexos fue en los párpados (53,4 %) y la conjuntiva (41,4 %). Los tipos histológicos predominantes fueron carcinoma basocelular palpebral (44,8 %) y carcinoma epidermoide de la conjuntiva (41,4 %). La estadificación del tumor se estableció: T1 en 47 pacientes, T2 y T3 en 4, así como T4 en 3. Conclusiones: El control del cáncer ocular es de suma importancia, pues permite trazar estrategias para el diagnóstico precoz y el tratamiento adecuado de los pacientes.

Introduction: The ocular neoplasm can affect the eye, annexes and orbit. The effective treatment depends on an early, presumptive and accurate diagnosis. Objective: To characterize patients with eye cancer according to variables of interest. Method: An observational, descriptive and retrospective study of 58 patients with eye malignancy confirmed by means of biopsy was carried out. They were assisted in the Ocular Plastic Surgery Service of the Ophthalmologic Center at Dr. Juan Bruno Zayas Alfonso Teaching General Hospital in Santiago de Cuba, from October, 2015 to the same period in 2020. The mean was used for the quantitative variables. Results: In the series the mean age was of 62.49 years; there was a prevalence of the male sex (51.7 %) and the mixed race color of the skin (53.4 %). The most frequent localization of the tumoral lesions in the annexes was in the lids (53.4 %) and the conjunctive (41.4 %). The predominant histologic types were palpebral basal cell carcinoma (44.8 %) and squamous cell carcinoma of the conjunctive (41.4 %). The estadification of the tumor was established: T1 en 47 patients, T2 and T3 in 4, as well as T4 in 3. Conclusions: The control of the eye cancer is very important, because it allows to trace strategies for the early diagnosis and the appropriate treatment of patients.